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Background: The human umbilical cord mesenchymal stem cells (hUCMSCs) have the ability to migrate into
tumors and therefore have been considered as an alternative source of mesenchymal progenitors for the therapy
of malignant diseases. The present study was aimed to investigate effect of hUCMSCs as vehicles for a constant
source of transgenic interleukin-21 (IL-21) on ovarian cancer in vivo.
Methods: The hUCMSCs were engineered to express IL-21 via lentiviral vector- designated ‘hUCMSCs-LV-IL-21’, and
then were transplanted into SKOV3 ovarian cancer xenograft-bearing nude mice. The therapeutic efficacy and
mechanisms of this procedure on ovarian cancer was evaluated.
Results: The isolated hUCMSCs were induced to differentiate efficiently into osteoblast and adipocyte lineages in vitro.
The expressed IL-21 in the supernatant from hUCMSCs-LV-IL-21 obviously stimulated splenocyte’s proliferation. The
hUCMSCs-LV-IL-21 significantly reduced SKOV3 ovarian cancer burden in mice indicated by tumor sizes compared with
control mice. The expressed IL-21 not only regulated the levels of IFN-γ and TNF-α in the mouse serum but also
increased the expression of NKG2D and MIC A molecules in the tumor tissues. The down regulation of β-catenin and
cyclin-D1 in the tumor tissues may refer to the inhibition of SKOV3 ovarian cancer growth in mice. In addition, hUCMSCs
did not form gross or histological teratomas up to 60 days posttransplantation in murine lung, liver, stomach and spleen.
Conclusion: These results clearly indicate a safety and usability of hUCMSCs-LV- IL-21 in ovarian cancer gene therapy,
suggesting the strategy may be a promising new method for clinical treatment of ovarian cancer.
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More than forty years ago, the study showed that cells
isolated from the stroma of bone marrow were capable
of osteogenesis, suggesting the characteristics of mesen-
chymal stem cells (MSCs) [1]. Subsequent studies have
demonstrated that MSCs exist not only in the bone mar-
row, but also in cord blood, cancellous bone, adipose tis-
sue, synovium and umbilical cord [2-7]. The human
umbilical cord contains an inexhaustible, noncontroversial* Correspondence: renmulan@seu.edu.cn; njdoujun@seu.edu.cn
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stated.source of stem cells [8]. Human umbilical cord mesenchy-
mal stem cells (hUCMSCs) grow as adherent cells with
mesenchymal morphology, have self-renewing, express
cell surface markers displayed by MSCs, and may be dif-
ferentiated into bone, cartilage, adipose, muscle, and
neural cells, etc. The properties promotes their potential
utility in several intractable human disease such as neuro-
degenerative disease, cancer, heart disease, etc. Since
hUCMSCs have the ability to migrate into tumors, they
could be used as vector for targeted cancer therapy [9,10].
There is increasing evidence that ovarian cancer is the
first leading cause of death among gynecologic malignan-
cies. The high mortality rate of ovarian cancer is usually
attributed to late diagnosis of this tumor due to a lack of
early symptoms. Even though the treatment of optimalLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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is initially effective in 80% of patients, recurrent cancer is
inevitable in the vast majority of cases. Furthermore, re-
curred tumors became unresponsive to the addition of
chemoradiation following an initial response [11,12]. The
second-and third-line (and beyond) therapies are aimed at
palliative care to prolong the time of tumor progression
and to improve the patient’s life quality [13]. Therefore,
the novel therapeutic strategies are desperately needed for
treatment of this malignant tumor [11].
In our previous studies, interleukin-21 (IL-21) was in-
volved in T and NK cell activation and induced a strong
cell-mediated immune responses in the tumor vaccine
approaches [14,15]. In fact, IL-21 has been extensively
applied to significantly augment antitumor immunity in
multiple murine tumor models and clinical trials, such
as metastatic lymphoma [16], melanoma [17,18], ovarian
cancer [19], etc. Previously, we constructed recombinant
pIRES2-IL-21-EGFP and transfected it into CD34+ hu-
man umbilical cord blood stem cells (UCBSCs) for treat-
ment of ovarian cancer. The animal experiment results
indicated that transferring CD34+ UCBSC- IL-21 into
A2780 ovarian cancer xenograft-bearing nude mice aug-
mented the therapeutic effect on ovarian cancer, how-
ever, IL-21 expression was gradually decreased in the
mouse tumor sites 21 days posttransplantation [20]. In
order to last the expression of IL-21 in tumor-bearing
mice, we used lentiviral vector as delivery of IL-21 in
this study. Accumulating evidence indicates that lenti-
viral vector has evolved as a benchmark tool for stable
gene transfer into cells with a high replicative potential
and provides a rich resource for numerous applications
in experimental platforms and therapeutic settings.
Since hUCMSCs have attracted much attention due to
their availability, low immunogenicity, as well as strong
tropism for tumors in contrast to hMSCs from other
sources [8-10], we particularly focused on the investigation
using hUCMSCs to express IL-21 via lentiviral vector to
assess the therapeutic effect of hUCMSCs- LV-IL-21 on
SKOV3 ovarian cancer xenograft-bearing mouse model in
the current study. Here, we show that hUCMSCs them-
selves do not form tumors, and that tumor growth in ovar-
ian cancer bearing mice is significantly inhibited following
systemic administration of IL-21-expressing hUCMSCs.
Methods
Cell lines, mice, and primers
Human ovarian cancer cell line SKOV-3 and human em-
bryonic kidney (HEK) 293T cells were purchased from
the Cellular Institute in Shanghai, China. SKOV-3 cells
were maintained in complete media consisting of RPMI
1640, 2 mmol/L-glutamine, 100 u/ml penicillin, 100 μg/ml
streptomycin, and 10% fetal bovine serum (FBS, Gibco
BRL, USA). HEK293T cells were cultured in DMEMmedium plus 10% FBS, 2 mmol/LL-glutamine, 100 u/ml
penicillin, and 100 μg/ml streptomycin. All cells were cul-
tured at 37°C in a humidified 5% CO2 atmosphere.
Balb/c nude mice of 4–5 weeks of age were acquired
from the Animal Center of Yang Zhou University of China
and were raised under sterile conditions in air-filtered
containers at the Experimental Animal Center, Medical
School of Southeast University. All the experiments were
performed in compliance with the guidelines of the Ani-
mal Research Ethics Board of Southeast University, China.
The used primer sequences are as follows:
The PCR primer sequence for IL-21 gene was 5′-
GGCGCTAGCATGGATCG CCTCCTGATTAGACTT-
3′ (sense), and 5′-TGCGCGGCGTCGGTGGAGAGAT
GCTGAT-3′ (antisense). The PCR primer for natural
killer glucoprotein 2 domain (NKG2D) gene was 5′-CT
CCATTTTTTTTCTGCTGCTTC-3′ (sense), and 5′-AAG
GCTGGCATTTTGAGACATAC-3′ (antisense). The PCR
primer for MICA gene was 5′-AAGACCAAGACACAC
TATCACGC-3′ (sense), and 5′-GGTGTCGTGGC TCAA
AGATAC-3′ (antisense). The PCR primer for actin gene
was 5′-GTCCACCG CAAATGCTTCTA-3′(sense), and
5′-TGCTGTCACCTTCACCGTTC-3′ (antisense). All the
primers were synthesized by Company of Gene and Tech-
nology of China in Shanghai.
Isolation and culture of hUCMSCs
All human umbilical cord blood samples were obtained
from the Department of Gynecology & Obstetrics of
Zhongda Hospital, Southeast University (Nanjing, Jiangsu,
China) and were used in accordance with the ethical
guidelines and accepted human studies protocols at
Southeast University School of Medicine. The length of
the umbilical cords in pregnancy (more than 37 weeks)
was about 15 cm. hUCMSCs were harvested as described
previously [21,22]. To ensure a homogeneous population
of stem cells, passage-4 cells were characterized by flow
cytometry (FCM) to analyze specific surface antigens of
MSC lineage including CD29, CD34, CD45, and CD90.
Approximately 106 cells per vial were used for each anti-
gen detection. Nonspecific binding was first blocked with
a staining buffer containing 2% FBS for 15 min, and cells
were then incubated with single label antigen for 20 min
on ice. Mouse isotype antigen served as a negative control.
FCM analysis was conducted using a FAC scan flow cyt-
ometer (BD Biosciences). Passage-4 hUCMSCs were used
to test the ability of osteoblastic and adipogenic differenti-
ation as described in a previous reports [23-25].
Construction of recombinant lentiviral vector containing
IL-21 gene
To generate the IL-21 expression lentivirus vector, we
amplified IL-21 by PCR from template plasmid pRSC-IL-
21 using the designed primers as aforesaid. The lentivirus
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from the transient transfection of the HEK293T cells with
pHAGE-CMV-IL-21-IZsGreen, psPAX2, and pMD2.G
plasmid DNAs (kindly provided by Professor Lu Chun,
Department of Microbiology and Immunology, Nanjing
Medical University, China) plus Lipofectamine 2000 (Invi-
trogen, USA) according to the manufacturer’s protocol
[26]. The IZsGreen expressed by HEK 293T cells was de-
tected using fluorescence microscopy.
Transduction and analysis of IL-21 expression
hUCMSCs were plated in 100 mm plates at 6 × 106 cells
per plate. After one day, the cells were 70% confluent. The
cells were incubated sequentially with the 48 hour and 72
hour lentivirus-IL-21 and lentivirus supernatants respect-
ively for 12 h. Following the last transduction, the cells
were washed and incubated with fresh growth medium to
allow puromycin-resistance expression. Two days later,
puromycin selection was performed by incubating the
cells in growth media supplemented with 1 μg/mL puro-
mycin (Clontech Laboratories Inc.) for five days. After se-
lection, hUCMSCs containing lentivirus-IL-21 (named
hUCMSCs-LV-IL-21) and hUCMSCs lentivirus without
IL-21 (named hUCMSCs-LV-Vec) were selected respect-
ively. Then IL-21 expression was analyzed by western blot-
ting. To identify the bioactivity of UCMSCs-LV-IL-21, the
splenocytes from the normal nude mice were incubated
with the supernatant from the cultured hUCMSCs-LV-IL-
21 for 72 h, then the splenocyte proliferative activity was
detected by FCM as described in a previous report [27].
Evaluation of gene therapy of ovarian cancer efficacy
Balb/c nude mice of 4–5 weeks of age were randomly
assigned to PBS control group, hUCMSCs group,
hUCMSCs-LV-Vec group, and hUCMSCs-LV-IL-21. In
establishing an ovarian cancer xenograft-bearing nude
mice model, 5 × 106 SKOV3 cells were subcutaneously
injected into a mouse’s right flank. About 7 days after the
injection, tumors were visible to the naked eye. Then,
100 μl PBS, 1 × 106 hUCMSCs or hUCMSCs-LV-Vec or
hUCMSCs-LV-IL-21 were injected into the mouse’s tumor
sites, and tumor growth was monitored each day. The
tumor volumes were evaluated every 3 days by measuring
two perpendicular diameters of the tumors using calipers
[28]. Three mice per group were used and the experiment
was repeated two times. All mice were sacrificed at 35
days after injection of different hUCMSCs. In addition,
1 × 106 hUCMSCs were injected into 5 nude mice to ob-
serve if the cells could form tumors by 60 days of
observation.
ELISA for IL-21, IFN-γ and TNF-α
Mouse serum cytokines were measured using a com-
mercially available enzyme-linked immunosorbent assay(ELISA) according to the manufacturer’s protocol
(eBioscience Company, USA). Briefly, samples were di-
luted 1:5 with PBS, and each cytokine was captured by the
specific primary monoclonal antibody and detected by
biotin labeled secondary antibody. The plates were read at
450 nm using a microplate reader (Bio-Rad Labs,
Hercules, CA). The samples and standards were run in
triplicate, and the sensitivity of the assays was 0.1 U/ml
for interferon-γ (IFN-γ), IL-21, and tumor necrosis factor-
α (TNF-α), respectively [29,30].
RNA isolation and quantitative RT-PCR
Total RNA was obtained using the Qiagen RNeasy kit
(Qiagen, CA). Isolated RNA samples were dissolved in
RNase-free water, and RNA quantity was measured
using NanoDrop (Thermo Fisher Scientific). cDNA was
synthesised from 10 μg of total RNA at a volume of
100 μl using ImProm RT-II™ (Promega) according to the
manufacturer’s instructions. cDNA samples were diluted
with sterile deionised water to a total volume of 100 μl,
and 2 μl was added to a PCR reaction. Quantitative RT-
PCR (qRT-PCR) was performed on an ABI step one plus
real-time system (Applied Biosystems, USA). We ana-
lyzed the relative expression levels of NKG2D and MIC
A genes using the primers described above [31].
Western blotting
The protocol was based on a previously published report
[32]. Briefly, 1 × 106 cells were collected and lyzed in a
protein extraction buffer (Novagen, WI) according to
the manufacturer’s protocol. Western blotting was per-
formed after 12% sodium dodecyl sulfate-polyacrylamide
gel electrophoresis and proteins (15 μg/lane) were elec-
trotransferred onto a nitrocellulose membrane. The
rabbit antibody specific to mouse IL-21 or human β-
catenin or human cyclin-D1 was added to the membrane
for 1 h, the membrane was washed for 5 min with anti-
body wash solution three times, and the subsequent
steps were performed according to the Western-Breeze
Kit’s protocol (Invitrogen). Immunoreactive bands were
detected by the Odyssey scanning instrument (LICOR
Odyssey, USA).
Histopathology of tissues and tumors
Mice were sacrificed 35 days (gene therapy of ovarian
cancer experiment) after the SKOV3 cell challenge or 60
days (tumor formation experiment) after the injection of
hUCMSCs. The tissues of the spleens, livers, stomachs,
and lungs as well as the tumor tissues were removed
from the nude mice and fixed in 10% formalin, and then
embedded in paraffin. Serial thin tissues and tumor sec-
tions (4 μm) were cut and mounted on SuperFrost Plus
glass slides, fixed in methanol, and stained in hematoxylin
and eosin (H&E) [33].
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4 μm formalin-fixed, paraffin embedded slides were in-
cubated with the rabbit anti human β-catenin antibody
or rabbit anti human cyclin-D1 antibody (Sigma) after
over night incubation at 4°C. The samples were then
labeled with horseradish peroxidase conjugated strepta-
vidin (Invitrogen) and the chromogenic reaction devel-
oped using liquid DAB substrate pack (Biogenex, San
Ramon, CA) according to the manufacturer’s instruc-
tions. β-catenin and cyclin-D1 stained cells from random
and non-overlapping fields were counted under a light
microscope, magnification of 200× [31].
Statistical analysis
Statistical comparisons were performed using the Stu-
dent’s t-test method or single factor analysis of variance to
test for any statistically significant differences in the results
between the experiment group and the control group. P <
0.05 was considered statistically significant. Analyses were
performed with the Graph Pad Prism 5.0 statistical soft-
ware package (Graph Pad Company, USA) [19].
Results
Culture and identification of hUCMSCs
The photo of hUCMSCs shows that the cells formed
whirlpool-like arrays and developed a defined spindle-
shaped fibroblastic morphology when a confluent mono-
layer (Figure 1A). The hUCMSCs in specific cultureFigure 1 Isolation and characteristic identification of hUCMSCs. Panel
Panels B-C exhibit that hUCMSCs were induced to differentiate into osteob
differentiation assays in vitro. Original magnification is 400×; Panels (D-H) i
different fluorescein isothiocyanate-labeled antibodies.medium were observed to differentiate efficiently into
osteoblast (Figure 1B) and adipocyte lineages (Figure 1C).
These cells showed good homogeneity and expressed
hUCMSC phenotypic characteristic markers such as
positive phenotypes of CD29, and CD90 and negative
phenotypes of CD34 and CD45 (Figure 1D-H). The data
indicated that hUCMSCs were developed appropriately,
which assists in the further study of hUCMSCs as vehicles
for IL-21 delivery via lentiviral to develop therapeutic ef-
fect on SKOV3 ovarian cancer xenograft-bearing nude
mice.
Transduction and analysis of IL-21 expression
Construction of recombinant lentiviral containing IL-21
gene was confirmed by gene sequencing. pHAGE-IL-21,
pMD2.G and psPAX2 were used to co-transfect the
HEK293T cells, and the IZsGreen expressed by HEK
293T cells was observed under a fluorescence micros-
copy (These data not shown). Next, we developed the
hUCMSCs-LV-IL-21 that were transducted with the
lentiviral-IL-21. Three days post transduction, the IZs-
Green expressed by hUCMSCs-LV-IL-21 cells was ob-
served under a light microscope (Figure 2A) and a
fluorescence microscopy (Figure 2B), respectively. The IL-
21 expression in hUCMSCs-LV-IL-21 was analyzed by
western blotting as is shown in Figure 2C. Whereafter, we
further identified the bioactivity of IL-21 expressed by
hUCMSCs-LV-IL-21. The isolated splenocytes from the(A) shows morphology of hUCMSCs at magnification 100×;
last (B) and adipogenesis (C) by osteogenic and adipogenic
ndicate that the cultured Passage-4 hUCMSCs were phenotyped with
Figure 2 Detection of IL-21 expression and its bioactivity in hUCMSCs transducted with recombinant lentiviral-IL-21. Panels A-B indicate
morphology of hUCMSCs transducted with recombinant lentiviral-IL-21 under a light microscope (A) and a fluorescence microscope (B) at
magnification 100×; C-D. IL-21 expression was identified by Western blotting (C) and relative expression of IL-21 (D); E-G. The effects of the
supernatants from the cultured control hUCMSCs (E), hUCMSCs-LV-Vec (F), and hUCMSCs-LV-IL-21 (G) on the splenocyte’s proliferative activity,
respectively; H. The statistical analysis of splenocyte’s proliferative activity. ***p < 0.005.
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from the cultured hUCMSCs- LV-IL-21 for 72 h.
Figure 2E-H indicate the proliferative activity of spleno-
cytes was significantly increased in the hUCMSCs-LV-IL-
21 group (44.59%, G) compared with the control group
(0.34%, E) and the hUCMSCs-LV-Vec group (0.75%, F),
respectively (P <0.005). This result suggested that the IL-
21 in the supernatant from cultured hUCMSCs-LV-IL-21
was functional, and that hUCMSCs would provide good
vehicle for further hUCMSCs-based IL-21 gene therapy of
ovarian cancer.
Efficacy of hUCMSCs-LV-IL-21 therapy for ovarian cancer
in nude mice and the related mechanism investigation
In order to evaluate the efficacy of hUCMSCs-LV-IL-21
therapy for ovarian cancer in the mice, we first estab-
lished the ovarian cancer bearing mouse model by injec-
tion of 5 × 106 SKOV3 cells in a mouse’s flank, and then
we tested whether injection of 1 × 106 hUCMSCs-LV-IL-
21 could inhibit the SKOV3 ovarian cancer growth in
the mouse model. Figure 3A shows that hUCMSCs-LV-
IL-21 obviously inhibited tumor growth compared with
control mice. There were significantly decreased of
tumor sizes in the hUCMSCs-LV-IL-21 group comparedwith the control group (p < 0.01), hUCMSCs group (p <
0.05) and hUCMSCs-LV-Vec group (p < 0.05), respect-
ively, but there was no significant difference in tumor
sizes between hUCMSCs group and hUCMSCs-LV-Vec
group (p > 0.05). To further analyze the mechanisms of
hUCMSCs- LV-IL-21 therapy for ovarian cancer in mice,
we designed an experiment to find out whether the
serum cytokines of IL-21, IFN-γ, and TNF-α were chan-
ged in the mice treated with hUCMSCs-LV-IL-21. The
results showed that the levels of IL-21, IFN-γ, and TNF-
α in nude mice treated with hUCMSCs-LV-IL-21 were
increased markedly in comparison with the control
group, hUCMSCs group and hUCMSCs-LV-Vec group,
respectively as are shown in Figure 3C-E. Furthermore,
we further identified whether IL-21 was expressed in
ovarian cancer tissues in the mice. Figure 3F indicates
that there was IL-21 protein expression in the tumor tis-
sues, which may suggest that hUCMSCs based IL-21
participated in the therapy of ovarian cancer. Given the
crucial role of NK cell activity in the immunosurveil-
lance of tumors, which are related with the expression
levels of NKG2D and MIC A molecules, we thus de-
tected the molecular transcript expression of NKG2D
and MIC A. Figure 3G-H show the results of mRNA
Figure 3 Inhibition of ovarian cancer growth in mice treated with hUCMSCs-LV-IL-21. A. The pictures represent the ovarian cancer bearing
mice at five weeks after challenge of 5 × 106 SKOV3 cells along with injection of various hUCMSCs; B. The tumor sizes were analyzed and
indicated the 301.03 ± 23.78 mm3, 219.80 ± 15.67 mm3, 200.96 ± 19.97 mm3 and 94.20 ± 15.57 mm3 in the mice treated with PBS control, the
hUCMSCs, hUCMSCs-LV-Vec and in the hUCMSCs-LV-IL-21 in order; C-E. Levels of IL-21, IFN-γ and TNF-α in murine serum were detected by ELISA
assay, respectively; F. IL-21 expression was shown in the tumor tissues from the mice treated with hUCMSCs-LV-IL-21. However, no specific IL-21
band was shown in the tumor tissues from the mice treated with hUCMSCs-LV-Vec, hUCMSCs and PBS, respectively; G-H. The mRNA expression
of NKG2D and MIC A detected by the real time RT-PCR in tumor tissues from the mice treated with hUCMSCs-LV-IL-21, hUCMSCs-LV-Vec,
hUCMSCs and PBS, respectively. *p < 0.05, **p < 0.01, and ***p < 0.005. ns: no statistical significant.
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in hUCMSCs-LV-IL-21 group, hUCMSCs-LV-Vec group,
hUCMSCs group and control group, respectively, in the
tumor tissues. The mRNA expression of NKG2D and MIC
A were actually upregulated in the mice treated with
hUCMSCs-LV-IL-21 group in contrast to the other groups.
These data suggested that hUCMSCs-LV-IL-21 could
markedly inhibited ovarian cancer growth in the mouse
model, and the elevated cytokines above-mentioned may
assist in hUCMSCs-LV-IL-21’s antitumor activity.
Down-regulation of β-catenin and cyclin-D1 in tumor tissues
It has been reported that hUCMSCs could inhibit tumor
growth through the regulation of Wnt signal transduction
pathway [34]. For this reason, we further investigatedwhether Wnt signal pathway was involved in the inhibi-
tory effect on ovarian cancer mediated by hUCMSCs-LV-
IL-21. The expression of β-catenin and cyclin-D1 was
tested by immunohistochemistry and western blotting, re-
spectively. As shown in Figure 4A, the results of western
blotting showed that the expression of β-catenin and
cyclin-D1 that is β-catenin target molecule was simultan-
eously down-regulated in tumor tissues of mice treated
with hUCMSCs-LV-IL-21 in comparison with the control
group, hUCMSCs group and hUCMSCs-LV-Vec group.
Consistent with the observed reduction in the expression
of β-catenin and cyclin-D1 detected by western blotting,
the results of immunohistochemistry indicated the expres-
sion of β-catenin and cyclin-D1 in tumor tissues of mice
treated with hUCMSCs-LV-IL-21 was also significantly
Figure 4 The expression of β-catenin and cyclin-D1 in tumor tissues. A. Western blotting results show the expression of β-catenin and
cyclin-D1 in the tumor tissues; B. Immunohistochemistry also shows the expression of β-catenin and cyclin-D1. It was found that the expression
of β-catenin and cyclin-D1 in tumor tissues from the mice treated with hUCMSCs-LV-IL-21 for four weeks was significantly decreased compared
with the hUCMSCs group and hUCMSCs-LV-Vec group or markedly decreased compared with the control group. *p < 0.05, **p < 0.01, and
***p < 0.005. ns: no statistical significant.
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group and hUCMSCs-LV-Vec group, respectively (Figure 4B).
The results implied that the secreted IL-21 from
hUCMSCs-LV-IL-21 may assist in the inhibition of ovar-
ian cancer growth in the mouse model by down-
regulation of β-catenin and cyclin-D1 expression in Wnt/
β-catenin signal transduction pathway.
Histological analysis of the spleen, liver, lung, stomach
and tumor tissues in the nude mice
All the mice were killed 60 days after injection of 1 × 106
hUCMSCs. In the 60-day observation, five nude mice
appeared healthy with no clinical symptoms. No visible
tumors were found around the transplantation sites or
in any other regions of mice. Histological analysis also
failed to detect any evidence of tumors in tissues such as
lung, liver, stomach, and spleen (Figure 5A-D). These re-
sults suggested that the hUCMSCs did not form tumors
in mice and thus could be potentially usable for
hUCMSCs-based studies. In addition, histopathological
analysis was also performed on the tumor tissues in thenude mice at 35 days. Figure 5E-H show that some
necrotic, apoptotic tumor cells or vascular bleeding (H,
arrows) may be attributable to increased tumoricidal ac-
tivities of tumor-infiltrating immunocytes. In contrast,
the active growth of the tumor cells and obvious nucleic
divisions or diverse nucleic types were found in the mice
challenged with the SKOV3 cells (E). It was also found
that a few of the tumor-infiltrating immunocytes and a
part of the apoptosis tumor cells were noticeable in the
tumor tissues of the mice treated with hUCMSCs (F)
and hUCMSCs-LV-Vec (G). The results of histological
analysis suggested that the hUCMSCs-LV-IL-21 could
induce nude mice to generate the immune responses to
the ovarian cancer SKOV3 cells.Discussion
In the study, we first constructed the recombinant lenti-
viral vector for lasting the expression of IL-21, and then
the hUCMSCs transducted by IL-21 gene packaged
lentivirus had been injected into mouse ovarian cancer
Figure 5 Histopathology of normal tissues and tumor tissues in the nude mice (H&E 100×). A-D. Absence of tumor formation in nude
mice injected with 1 × 106 hUCMSCs for 60 days. The tissue sections of lung (A), liver (B), stomach (C) and spleen (D) show no presence of any
tumor cells; E-H. The tumor tissue histopathological sections were made in mice of the control group (E), the hUCMSCs group (F), the hUCMSCs-
LV-Vec group (G), and the hUCMSCs-LV- IL-21 group (H), respectively. Section E shows the active growth of the tumor cells and obvious nucleic
divisions. A few of the apoptosis tumor cells were observed in the tumor tissues of the mice treated with hUCMSCs (F) and hUCMSCs-LV-Vec (G),
but a little more necrotic, apoptotic tumor cells were found in Section H, which was collected from the tumor tissues from the mice treated with
the hUCMSCs-LV-IL-21 group.
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ovarian cancer in vivo.
Our experimental results showed that hUCMSCs-LV-
IL-21 induced powerful tumoricidal activities against hu-
man ovarian tumor in the xenograft-bearing Balb/c
nude mouse model after the injection of SKOV3 cells.
This effectiveness was reflected in the tumors showing
slower growth and the smaller sizes (Figure 3), in the
tumor cell necrosis, and in the observation that the vas-
cular bleeding was more obvious in the tumor tissues of
mice treated with hUCMSCs-LV-IL-21 group than other
groups (Figure 5H).
The IL-21 secreted by the hUCMSCs-LV-IL-21 may
stimulate the innate immune response to SKOV3 ovar-
ian cells as well as induce hUCMSCs-LV-IL-21 to dif-
ferentiate more immune cells, enhance the immune
activity, and play a key role in killing tumor cells or drive
tumor cell apoptosis. Although hUCMSCs can also elicit
antitumor immune responses in contrast to the control
group, this antitumor efficacy was especially true of the
mice transplanted with hUCMSCs-LV-IL-21 that secrete
IL-21 for long time.
To understand the mechanisms of antitumor efficacy
induced by hUCMSCs- LV-IL-21, we examined the
serum cytokines of IL-21, IFN-γ, and TNF-α, which have
an important functions in antitumor immunity and theirlevels indirectly represent the capacity of rejection of
tumor in bearing-tumor nude mice. The secreted IL-21
by hUCMSCs-LV-IL-21 can induce secondary cytokine
production. The secreted IFN-γ and TNF-α by the NK
cells or the macrophage, particularly the IFN-γ, can react
to the NK cells, increase its cytotoxic activity, and play a
key role in killing tumor cells or induce tumor cell apop-
tosis. The presented data showed that the IL-21, IFN-γ
and TNF-α were respectively enhanced in the mice
treated with hUCMSCs-LV-IL-21 group compared with
other groups. Although it has been shown that serum
levels of cytokines delivered by engineered stem cells
have no obvious role in contrast to cytokine given sys-
temically, the local production of cytokine appears to be
the key for tumor growth attenuation. The stem cell-
based gene therapy can also avoid potential systemic
adverse effect of cytokines [35]. We speculate that
hUCMSCs-LV-IL-21 elevated IFN-γ and TNF-α related
to the secretion of IL-21, and that the elevated IFN-γ
and TNF-α might markedly enhance the NK cytotoxicity
that was supported by increase of expression of NKG2D
and MIC A in the tumor tissues of the mice treated with
hUCMSCs-LV-IL-21group. The enhanced NK cytotox-
icity may be closely associated with the tumor cell ne-
crosis, apoptosis, and the vascular bleeding in the tumor
tissues (Figure 5H).
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tion of cytosolic β-catenin, nuclear translocation, and gene
regulation. Genes regulated by Wnt signaling are involved
in metabolism, proliferation, cell cycle, and apoptosis [36].
Therefore, the proliferation of tumor cells can be influ-
enced by regulating canonical Wnt signaling pathway
[34,37]. It has been suggested that hUCMSCs could in-
hibit tumor growth through the regulation of this pathway
[34]. We supposed that canonical Wnt signaling pathway
might be involved in the inhibitory effects on ovarian can-
cer cells mediated by hUCMSCs-LV-IL-21. To test the
hypothesis, we examined the molecular expression of β-
catenin in tumor tissues. The results of western blotting
and immunohistochemistry showed that the expression of
β-catenin was down regulated in tumor tissues of mice
treated with hUCMSCs, hUCMSCs-LV-Vec and hUCMSCs-
LV-IL-21, respectively, especially in the hUCMSCs-LV-IL-
21 group. To further evaluate whether known β-catenin
target molecule was also reduced, we analyzed the expres-
sion of cyclin-D1. Consistent with the observed reduction
in β-catenin, the cyclin-D1 expression was also down-
regulated in same samples. We guess that the hUCMSCs-
LV-IL-21 reduced β-catenin expression and might de-
crease β-catenin translocation to the nucleus to decrease
the expression of cyclin-D1 that may reduce the transcrip-
tion of its specific target gene, resulting in inhibition of
tumor cell growth [34].
In conclusion, our data show that hUCMSCs display
very similar characteristics to bone marrow-MSCs and
could represent a valuable alternative for cell-based ther-
apies. Transplanting hUCMSCs-LV-IL-21 into SKOV3
ovarian cancer xenograft-bearing nude mice has a defin-
ite therapeutic effect on inhibition of ovarian cancer
growth. This augmented the therapeutic efficacy may
contribute to the secreted IL-21 from hUCMSCs-LV-IL-
21 and increase of the expression of NKG2D and MIC
A, and assisting in exerting an antitumor effect through
augmenting NK cytotoxicity. We speculate that the
hUCMSCs-LV-IL-21 play an anti-tumor effect through
regulating canonical Wnt signaling pathway. A more de-
tailed understanding of the β-catenin and cyclin-D1 role
in Wnt signaling pathway may be helpful in the investi-
gation of the molecular mechanisms presented in
hUCMSCs-LV-IL-21, and may improve therapeutic
strategies involving hUCMSCs-LV-IL-21-mediated tar-
geting therapy of ovarian cancer.
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